Gonadotrophin replacement for induction of fertility in hypogonadal men

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 29, Issue 1, 2015, Pages 91-103

  Dwyer, Andrew A ^a   Raivio, Taneli ^b,c   Pitteloud, Nelly ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Fertility outcomes; Fertility treatment; GnRH deficiency; Gonadotrophin therapy; Hypogonadotrophic hypogonadism; Kallmann syndrome; Male fertility

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN; GONADOTROPIN; FOLLITROPIN;

CONGENITAL HYPOGONADOTROPHIC HYPOGONADISM; GENETICS; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY THERAPY; MALE; MALE FERTILITY; MEDICAL LITERATURE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; REPRODUCTIVE BEHAVIOR; REVIEW; COMPLICATION; DEFICIENCY; INFERTILITY, MALE; TREATMENT OUTCOME;

FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOGONADISM; INFERTILITY, MALE; MALE; TREATMENT OUTCOME;

EID: 84927926426     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.10.005     Document Type: Review

References (99)

1. Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978; 202: 631-3.
2. Bianco SD, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009; 5: 569-76.
3. Mitchell AL, Dwyer A, Pitteloud N, et al. Genetic basis and variable phenotypic expression of Kallmann syndrome: Towards a unifying theory. Trends Endocrinol Metab 2011; 22: 249-58.
4. Hutson JM, Southwell BR, Li R, et al. The regulation of testicular descent and the effects of cryptorchidism. Endocr Rev 2013; 34: 725-52.
5. Kuiri-Hanninen T, Sankilampi U, Dunkel L. Activation of the hypothalamic-pituitary-gonadal axis in infancy: Minipuberty. Horm Res Paediatr 2014; 82: 73-80.
6. Grumbach MM. A window of opportunity: The diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 2005; 90: 3122-7.
7. Muller J, Skakkebaek NE. Quantification of germ cells and seminiferous tubules by stereological examination of testicles from 50 boys who suffered from sudden death. Int J Androl 1983; 6: 143-56.
8. Boyar RM, Rosenfeld RS, Kapen S, et al. Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. J Clin Investig 1974; 54: 609-18.
9. Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: An extended classification based on a developmental, endocrine physiology-based approach. Andrology 2013; 1: 3-16.
10. Russell LD, Ren HP, Sinha Hikim I, et al. A comparative study in twelve mammalian species of volume densities, volumes, and numerical densities of selected testis components, emphasizing those related to the sertoli cell. Am J Anat 1990; 188: 21-30.
11. Orth JM, Gunsalus GL, Lamperti AA. Evidence from sertoli cell-depleted rats indicates that spermatid number in adults depends on numbers of sertoli cells produced during perinatal development. Endocrinology 1988; 122: 787-94.
12. Sharpe RM, Turner KJ, McKinnell C, et al. Inhibin B levels in plasma of the male rat from birth to adulthood: Effect of experimental manipulation of sertoli cell number. J Androl 1999; 20: 94-101.
13. Young J, Rey R, Couzinet B, et al. Antimullerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84: 2696-9.
14. Hero M, Tommiska J, Vaaralahti K, et al. Circulating antimullerian hormone levels in boys decline during early puberty and correlate with inhibin B. Fertil Steril 2012; 97: 1242-7.
15. Rey RA, Musse M, Venara M, et al. Ontogeny of the androgen receptor expression in the fetal and postnatal testis: Its relevance on sertoli cell maturation and the onset of adult spermatogenesis. Microsc Res Tech 2009; 72: 787-95.
16. Schaison G, Young J, Pholsena M, et al. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1993; 77: 1545-9.
17. Matsumoto AM, Karpas AE, Bremner WJ. Chronic human chorionic gonadotropin administration in normal men: Evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man. J Clin Endocrinol Metab 1986; 62: 1184-92.
18. Fromantin M, Gineste J, Didier A, et al. Impuberism and hypogonadism at induction into military service. Statistical study. Problemes actuels d'endocrinologie de Nutr 1973; 16: 179-99.
19. Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2012; 97: 707-18.
20. Pitteloud N, Hayes FJ, Boepple PA, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87: 152-60.
21. Hoffman AR, Crowley Jr. WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982; 307: 1237-41.
22. Delemarre-Van deWaal HA. Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone in patients with hypogonadotrophic hypogonadism. Clin Endocrinol 1993; 38: 473-80.
23. Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med 1985; 313: 651-5.
24. Vicari E, Mongioi A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadismelong-term follow-up. Int J Androl 1992; 15: 320-9.
25. Liu L, Banks SM, Barnes KM, et al. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988; 67: 1140-5.
26. Schopohl J, Mehltretter G, von Zumbusch R, et al. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertil Steril 1991; 56: 1143-50.
27. Buchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: A review of 42 cases. Eur J Endocrinol 1998; 139: 298-303.
28. Burris AS, Rodbard HW, Winters SJ, et al. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: The response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988; 66: 1144-51.
29. Pitteloud N, Hayes FJ, Dwyer A, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87: 4128-36.
30. Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: A 30-year retrospective study. J Urol 2005; 173: 2072-5.
31. Liu PY, Baker HW, Jayadev V, et al. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: Predictors of fertility outcome. J Clin Endocrinol Metab 2009; 94: 801-8.
32. Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009; 92: 594-604.
33. Liu PY, Gebski VJ, Turner L, et al. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum Reprod 2002; 17: 625-33.
34. Young J, Chanson P, Salenave S, et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90: 724-8.
35. Ley SB, Leonard JM. Male hypogonadotropic hypogonadism: Factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. J Clin Endocrinol Metab 1985; 61: 746-52.
36. Kirk JM, Savage MO, Grant DB, et al. Gonadal function and response to human chorionic and menopausal gonadotrophin therapy in male patients with idiopathic hypogonadotrophic hypogonadism. Clin Endocrinol 1994; 41: 57-63.
37. Chan E, Wayne C, Nasr A, , et alFRCSC for Canadian Association of Pediatric Surgeon Evidence-Based Resource. Ideal timing of orchiopexy: A systematic review. Pediatr Surg Int 2014; 30: 87-97.
38. Trsinar B, Muravec UR. Fertility potential after unilateral and bilateral orchidopexy for cryptorchidism.World J Urol 2009; 27: 513-9.
39. Lee PA, O'Leary LA, Songer NJ, et al. Paternity after unilateral cryptorchidism: A controlled study. Pediatrics 1996; 98: 676-9.
40. Kollin C, Stukenborg JB, Nurmio M, et al. Boys with undescended testes: Endocrine, volumetric and morphometric studies on testicular function before and after orchidopexy at nine months or three years of age. J Clin Endocrinol Metab 2012; 97: 4588-95.
41. Ritzen EM, Bergh A, Bjerknes R, et al. Nordic consensus on treatment of undescended testes. Acta Paediatr 2007; 96: 638-43.
42. Biers SM, Malone PS. A critical appraisal of the evidence for improved fertility indices in undescended testes after gonadotrophin-releasing hormone therapy and orchidopexy. J Pediatr Urol 2010; 6: 239-46.
43. Dunkel L, Taskinen S, Hovatta O, et al. Germ cell apoptosis after treatment of cryptorchidism with human chorionic gonadotropin is associated with impaired reproductive function in the adult. J Clin Investig 1997; 100: 2341-6.
44. Heiskanen P, Billig H, Toppari J, et al. Apoptotic cell death in the normal and cryptorchid human testis: The effect of human chorionic gonadotropin on testicular cell survival. Pediatr Res 1996; 40: 351-6.
45. Bouvattier C, Maione L, Bouligand J, et al. Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nat Rev Endocrinol 2012; 8: 172-82.
46. Burger HG, de Kretser DM, Hudson B, et al. Effects of preceding androgen therapy on testicular response to human pituitary gonadotropin in hypogonadotropic hypogonadism: A study of three patients. Fertil Steril 1981; 35: 64-8.
47. de Kretser DM, Kerr JB, Paulsen CA. The peritubular tissue in the normal and pathological human testis. An ultrastructural study. Biol Reprod 1975; 12: 317-24.
48. Maddock WO, Nelson WO. The effects of chorionic gonadotropin in adult men: Increased estrogen and 17-ketosteroid excretion, gynecomastia, leydig cell stimulation and semi-niferous tubule damage. J Clin Endocrinol Metab 1952; 12: 985-1014.
49. Kumar PA, Pitteloud N, Andrews PA, et al. Testis morphology in patients with idiopathic hypogonadotropic hypogonadism. Hum Reprod 2006; 21: 1033-40.
50. Barrio R, de Luis D, Alonso M, et al. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999; 71: 244-8.
51. Sykiotis GP, Plummer L, Hughes VA, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U. S. A 2010; 107: 15140-4.
52. Costa-Barbosa FA, Balasubramanian R, Keefe KW, et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J Clin Endocrinol Metab 2013; 98: E943-53.
53. Sykiotis GP, Hoang XH, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: Evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab 2010; 95: 3019-27.
54. Au MG, Crowley Jr. WF, Buck CL. Genetic counseling for isolated GnRH deficiency. Mol Cell Endocrinol 2011; 346: 102-9.
55. Aulitzky W, Frick J, Galvan G. Pulsatile luteinizing hormone-releasing hormone treatment of male hypogonadotropic hypogonadism. Fertil Steril 1988; 50: 480-6.
56. Spratt DI, Finkelstein JS, O'Dea LS, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone's physiologic effects. Ann Intern Med 1986; 105: 848-55.
57. Kung AW, Zhong YY, Lam KS, et al. Induction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadism. Int J Androl 1994; 17: 241-7.
58. McCullagh EP, Beck JC, Schaffenburg CA. A syndrome of eunuchoidism with spermatogenesis, normal urinary FSH and low or normal ICSH: (fertile eunuchs) . J Clin Endocrinol Metab 1953; 13: 489-509.
59. Pitteloud N, Boepple PA, DeCruz S, et al. The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: Spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 2001; 86: 2470-5.
60. Yang L, Zhang SX, Dong Q, et al. Application of hormonal treatment in hypogonadotropic hypogonadism: More than ten years experience. Int Urol Nephrol 2012; 44: 393-9.
61. European Metrodin HP Study Group. Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. Fertil Steril 1998; 70: 256-62.
62. Mannaerts B, Fauser B, Lahlou N, et al. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. Fertil Steril 1996; 65: 406-10.
63. Jones TH, Darne JF. Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clin Endocrinol 1993; 38: 203-8.
64. Burgues S, Calderon MD, Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Subcutaneous selfadministration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Hum Reprod 1997; 12: 980-6.
65. Saal W, Happ J, Cordes U, et al. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril 1991; 56: 319-24.
66. Verbost P, Sloot WN, Rose UM, et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011; 651: 227-33.
67. Okuyama A, Nakamura M, Namiki M, et al. Testicular responsiveness to long-term administration of hCG and hMG in patients with hypogonadotrophic hypogonadism. Horm Res 1986; 23: 21-30.
68. Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertil Steril 1995; 63: 1326-8.
69. Ishikawa T, Ooba T, Kondo Y, et al. Assessment of gonadotropin therapy in male hypogonadotropic hypogonadism. Fertil Steril 2007; 88: 1697-9.
70. Farhat R, Al-zidjali F, Alzahrani AS. Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism. Pituitary 2010; 13: 105-10.
71. Oldereid NB, Abyholm T, Tanbo TG. Spermatogenesis and fertility outcome in male hypogonadotrophic hypogonadism. Hum Fertil 2010; 13: 83-9.
72. Milsom S, Duggan K, O'Sullivan S, et al. Treatment of infertility with hypogonadotropic hypogonadism: 10-year experience in Auckland, New Zealand. Aust N Z J Obstet Gynaecol 2012; 52: 293-8.
73. Bouloux P, Warne DW, Loumaye E, et al. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertil Steril 2002; 77: 270-3.
74. Bouvattier C, Tauber M, Jouret B, et al. Gonadotropin treatment of hypogonadotropic hypogonadal adolescents. J Pediatr Endocrinol Metab 1999; 12: 339-44.
75. Bouloux PM, Nieschlag E, Burger HG, et al. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J Androl 2003; 24: 604-11.
76. Liu PY, Turner L, Rushford D, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod 1999; 14: 1540-5.
77. Matsumoto AM, Snyder PJ, Bhasin S, et al. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f) : Long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril 2009; 92: 979-90.
78. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol 2010; 72: 731-7.
79. Raivio T, Toppari J, Perheentupa A, et al. Treatment of prepubertal gonadotrophin-deficient boys with recombinant human follicle-stimulating hormone. Lancet 1997; 350: 263-4.
80. Raivio T, Wikstrom AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: Long-term observation and outcome. Eur J Endocrinol 2007; 156: 105-11.
81. Bougneres P, Francois M, Pantalone L, et al. Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. J Clin Endocrinol Metab 2008; 93: 2202-5.
82. Dwyer AA, Sykiotis GP, Hayes FJ, et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013; 98: E1790-5.
83. Padron RS, Wischusen J, Hudson B, et al. Prolonged biphasic response of plasma testosterone to single intramuscular injections of human chorionic gonadotropin. J Clin Endocrinol Metab 1980; 50: 1100-4.
84. Jones TH, Darne JF, McGarrigle HH. Diurnal rhythm of testosterone induced by human chorionic gonadotrophin (hCG) therapy in isolated hypogonadotrophic hypogonadism: A comparison between subcutaneous and intramuscular hCG administration. Eur J Endocrinol 1994; 131: 173-8.
85. Sokol RZ, McClure RD, Peterson M, et al. Gonadotropin therapy failure secondary to human chorionic gonadotropininduced antibodies. J Clin Endocrinol Metab 1981; 52: 929-32.
86. Trabado S, Maione L, Bry-Gauillard H, et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: A Single-Center study of 281 patients. J Clin Endocrinol Metab 2013; 99: E268-275.
87. Anawalt BD. Approach to male infertility and induction of spermatogenesis. J Clin Endocrinol Metab 2013; 98: 3532-42.
88. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010; 16: 231-45.
89. Burris AS, Clark RV, Vantman DJ, et al. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy. Fertil Steril 1988; 50: 343-7.
90. Depenbusch M, von Eckardstein S, Simoni M, et al. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol 2002; 147: 617-24.
91. Yong EL, Lee KO, Ng SC, et al. Induction of spermatogenesis in isolated hypogonadotrophic hypogonadism with gonadotrophins and early intervention with intracytoplasmic sperm injection. Hum Reprod 1997; 12: 1230-2.
92. Zorn B, Pfeifer M, Virant-Klun I, et al. Intracytoplasmic sperm injection as a complement to gonadotrophin treatment in infertile men with hypogonadotrophic hypogonadism. Int J Androl 2005; 28: 202-7.
93. Resorlu B, Abdulmajed MI, Kara C, et al. Is intracytoplasmic sperm injection essential for the treatment of hypogonadotrophic hypogonadism? A comparison between idiopathic and secondary hypogonadotrophic hypogonadism. Hum Fertil 2009; 12: 204-8.
94. Fahmy I, Kamal A, Shamloul R, et al. ICSI using testicular sperm in male hypogonadotrophic hypogonadism unresponsive to gonadotrophin therapy. Hum Reprod 2004; 19: 1558-61.
95. Bakircioglu ME, Erden HF, Ciray HN, et al. Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic hypogonadism. Reprod Biomed Online 2007; 15: 156-60.
96. Krabchi K, Berthaut I, Chantot-Bastaraud S, et al. Quality assessment of induced spermatogenesis in hypogonadotrophic hypogonadic men treated with gonadotrophins. Reprod Biomed Online 2011; 22: 277-83.
97. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N. Engl J Med 2002; 346: 725-30.
98. Reefhuis J, Honein MA, Schieve LA, et al. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 2009; 24: 360-6.
99. Shiraishi K, Oka S, Matsuyama H. Assessment of quality of life during gonadotrophin treatment for male hypogonadotrophic hypogonadism. Clin Endocrinol 2014; 81: 259-65.